Abstract
Background and Objective: The co-morbidity of depressive disorder and chronic kidney failure is remarkably common. However, knowledge about the influence of haemodialysis on the serum concentration of antidepressants is sparse. In this study we examined the influence of haemodialysis on the serum concentrations of the antidepressants amitriptyline (and its active metabolite nortriptyline) and mirtazapine.
Methods: The authors retrospectively evaluated therapeutic drug monitoring (TDM)-analyses obtained in eight different regional medical dialysis centres before and after haemodialysis and compared serum concentrations of amitriptyline and mirtazapine using t-tests.
Results: Mean serum concentrations of the sum of amitriptyline+nortriptyline (before: 75.52 ng/mL; after: 59.35 ng/mL; p < 0.001) and mirtazapine (before: 53.45 ng/mL; after: 38.31 ng/mL; p < 0.036) decreased significantly with haemodialysis. Haemodialysis patients received rather low doses of amitriptyline (mean 36.5mg; SD 17.6; range 10–75mg) and mirtazapine (mean 24.7mg; SD 9.1; range 15–45mg).
Conclusion: For haemodialysis patients with depression an adequate antidepressant drug dosage must be administered. TDM is necessary in order to optimize antidepressant therapy in patients with chronic kidney disease.
This is a preview of subscription content, log in via an institution to check access.
References
Hiemke Baumann P, Bergemann N, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195–235
Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–47
Balogun RA, Turgut F, Balogun SA, et al. Screening for depression in elderly hemodialysis patients. Nephron Clin Pract 2011; 118: c72–7
Chen CK, Tsai YC, Hsu HJ, et al. Depression and suicide risk in hemodialysis patients with chronic renal failure. Psychosomatics 2010; 51: 528e
Kimmel PL. Depression in patients with chronic renal disease: what we know and what we need to know. J Psychosom Res 2002; 53: 951–6
Kimmel PL, Cukor D, Cohen SD, et al. Depression in end-stage renal disease patients: a critical review. Adv Chronic Kidney Dis 2007; 14: 328–34
Martiny C, de Oliveira E, Silva AC, et al. Factors associated with risk of suicide in patients with hemodialysis. Compr Psychiatry 2011; 52: 465–8
Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14: 82–99
Lopes AA, Albert JM, Young EW, et al. Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 2004; 66: 2047–53
Kim YK, Park CS, Ihm SH, et al. Relationship between the course of depression symptoms and the left ventricular mass index and left ventricular filling pressure in chronic haemodialysis patients. Nephrology 2011; 16: 180–6
Kimmel PL, Peterson RA, Weihs KL, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000; 57: 2093–8
Lopes AA, Bragg J, Young E, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 2002; 62: 199–207
Hiemke C. Clinical utility of drug measurements and pharmacokinetics: therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol 2008; 64: 159–66
Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52: 5–9
Hiemke C. Therapeutisches Drug Monitoring von Antidepressiva und Neuroleptika. Methodische Voraussetzungen. Psychopharmakotherapie 1995; 2: 21–3
Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM “nouveau”. Ther Drug Monit 2006; 26: 145–51
Böhler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int 1999; 56: S24–8
Cohen LM, Tessier EG, Germain MJ, et al. Update on psychotropic medication use in renal disease. Psychosomatics 2004; 45: 34–48
Raymond CB, Wazny LD, Honcharik PL. Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease. Nephrol Nurs J 2008; 35: 257–63
Schlotterbeck PM, Vehren T, Milenovic S, et al. No influence of dialysis on mirtazapine: a case report. Pharmacopsychiatry 2008; 41: 259–60
Baghdady NT, Banik S, Swartz SA, et al. Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther 2009; 26: 404–24
Dawling S, Lynn K, Rosser R, et al. The pharmacokinetics of nortriptyline in patients with chronic renal failure. Br J Clin Pharmacol 1981; 12: 39–45
Dawling S, Lynn K, Rosser R, et al. Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clin Pharmacol Ther 1982; 32: 322–9
Tasset JJ, Singh S, Pesce AJ. Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. Ther Drug Monit 1985; 7: 255–7
Acknowledgements
We gratefully acknowledge the participating haemodialysis centres in Würzburg, Ochsenfurt, Kitzingen, Lohr, Aschaffenburg, Marktheidenfeld, Schweinfurt and Wertheim as well as Rainer Burger and the staff of the TDM laboratory of the Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg.
The authors have no conflicts of interest. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Unterecker, S., Müller, P., Jacob, C. et al. Therapeutic Drug Monitoring of Antidepressants in Haemodialysis Patients. Clin Drug Invest 32, 539–545 (2012). https://doi.org/10.1007/BF03261907
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03261907